Cardinal Health, Inc. (BCBA:CAH)
Argentina
· Delayed Price · Currency is ARS | Market Cap | 67.19T |
| Revenue (ttm) | 355.12T |
| Net Income (ttm) | 2.41T |
| Shares Out | n/a |
| EPS (ttm) | 10,078.90 |
| PE Ratio | 27.86 |
| Forward PE | 18.29 |
| Dividend | 580.62 (0.57%) |
| Ex-Dividend Date | Apr 1, 2026 |
| Volume | 81 |
| Average Volume | 178 |
| Open | 102,975 |
| Previous Close | 102,850 |
| Day's Range | 102,800 - 103,475 |
| 52-Week Range | 54,400 - 115,625 |
| Beta | n/a |
| RSI | 48.49 |
| Earnings Date | Apr 30, 2026 |
About Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products.... [Read more]
Financial Performance
In fiscal year 2025, Cardinal Health's revenue was $222.58 billion, a decrease of -1.87% compared to the previous year's $226.83 billion. Earnings were $1.56 billion, an increase of 83.22%.
Financial numbers in USDNews
Cramer says look to these 4 stocks to go with your high-flying tech names
CNBC's Jim Cramer urged investors to look at parts of the market that have already been beaten down. He highlighted four stocks in the health-care sector as alternatives to high-flying technology and ...
Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes. DUBLIN, O...
Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies
DUBLIN, Ohio, April 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for Theranos...
Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30
DUBLIN, Ohio, March 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2026 on April 30 as previously indicated, prior to the ope...
Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair
DUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B.
Cardinal Health Transcript: Barclays 28th Annual Global Healthcare Conference
Strong first-half results were driven by robust demand, effective execution, and strategic investments, leading to raised guidance across all business segments. The company’s differentiated M&A strategy and focus on specialty areas, combined with operational improvements and a disciplined capital framework, position it for continued growth amid favorable market trends and industry changes.
Cardinal Health Transcript: Leerink Global Healthcare Conference 2026
Strong demand and operational excellence have driven double-digit profit growth across all business segments, with specialty and at-home care as key growth drivers. Strategic acquisitions, integration of technology, and disciplined capital allocation are positioning the company for sustained success amid regulatory and market changes.
Cardinal Health report highlights cost savings and provider confidence in biosimilars
New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains. DUBLIN, Ohio...
Cardinal Health Board of Directors Approves Quarterly Dividend
DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital s...
Cardinal Health Stock Roars Higher. Another Guidance Boost Can Do That.
The pharmaceutical distributor and health services company raises its guidance for the second time.
Cardinal Health Earnings Call Transcript: Q2 2026
Q2 saw 19% revenue growth and 36% EPS growth, with all segments delivering double-digit profit gains. Fiscal 2026 EPS guidance was raised, driven by strong specialty, generics, and growth businesses, while disciplined capital allocation and operational improvements support long-term value.
Cardinal Health boosts annual profit forecast banking on surging demand for specialty drugs
Cardinal Health on Thursday raised its expectations for annual profit after surpassing Wall Street estimates for quarterly results, as it bets on robust demand for specialty medicines and strong perfo...
Cardinal Health Lifts Outlook After Posting Higher Profit
Cardinal Health raised its outlook for the year after logging higher profit and revenue in its fiscal second quarter.
Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook
Revenue increased 19% to $65.6 billion GAAP 1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97 Non-GAAP operating earnings increased 38% to $877 million; non-G...
Cardinal Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
EPS is projected to reach at least $10 by fiscal 2026, supported by strong specialty growth, resilient business models, and disciplined capital allocation. Investments in specialty, at-home, and nuclear businesses, along with demographic trends and innovation, are driving robust, broad-based growth.
Cardinal Health Stock Jumps on Guidance Raise. Why 2026 Will Be a Good Year.
The healthcare services company says it expects to bring in over $50 billion in specialty revenue in fiscal 2026.
Cardinal Health raises 2026 profit forecast
Cardinal Health on Tuesday forecast 2026 adjusted profit to be at least $10 per share, compared with its prior projection of $9.65 to $9.85 per share.
Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation
Raising Fiscal 2026 Outlook: Cardinal Health is increasing expectations for fiscal year 2026 non-GAAP diluted earnings per share (EPS)1 to at least $10.00, from its prior guidance range of $9.65 to $9...
Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2026 on February 5
DUBLIN, Ohio, Jan. 6, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the ...
These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.
With a 58% gain, CVS Health had its best year since 1982—and it wasn't the only strong performer.
Cardinal Health Transcript: Citi Annual Global Healthcare Conference 2025
Double-digit profit growth was achieved across all segments, with strong demand and execution in pharma, specialty, and generics. The MSO and nuclear businesses are driving higher-margin growth, while regulatory and pricing changes are being managed proactively. Capital deployment focuses on high ROI investments, shareholder returns, and selective M&A.
Cardinal Health Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong Q1 performance was driven by double-digit growth across all segments, new customer wins, and successful integration of acquisitions. Strategic partnerships, a robust generics pipeline, and disciplined capital allocation support a positive outlook, with ongoing investments in innovation and technology.
Cardinal Health Transcript: UBS Global Healthcare Conference 2025
Strong profit growth was achieved across all segments, led by pharma and specialty, with new business onboarding and operational improvements driving results. Specialty strategy focuses on diversified 'otherologies,' while investments in automation and acquisitions support future growth. Guidance was raised, and the company remains confident in its essential healthcare role.